drugset / Trial / NCT07520006
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Timeline
- Start
- 2026-05
- Primary completion
- 2033-05
- Completion
- 2033-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NX-5948 | Other / unclassified | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |